Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945168 | 0.89 | PARP1 (0.40) | OPRK1OPRM1CNR2CNR1PARP1 | |
| SCHEMBL20945266 | 0.81 | KCNH2 (0.37) | OPRK1OPRM1CNR2CNR1LTA4H | |
| SCHEMBL20944986 | 0.79 | LTA4H (0.48) | CNR2CNR1LTA4H | |
| SCHEMBL6302641 | 0.78 | CNR2 (0.41) | CNR2CNR1LTA4HPARP1 | |
| SCHEMBL6310595 | 0.76 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL12264182 | 0.75 | CNR2 (0.43) | OPRK1OPRM1CNR2CNR1KCNA3 | |
| SCHEMBL20945008 | 0.72 | ELANE (0.40) | CNR2CNR1PARP1 | |
| SCHEMBL28960037 | 0.70 | PDCD1 (0.44) | LTA4HKCNA3HRH2HRH1HRH3 | |
| SCHEMBL20945135 | 0.69 | KMT2A (0.47) | CNR2CNR1PARP1 | |
| SCHEMBL20689240 | 0.69 | TYK2 (0.38) | CNR2CNR1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | OPRK1 3066/4885OPRM1 3360/4885CNR2 4304/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | OPRK1 3066/4885OPRM1 3360/4885CNR2 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.